Literature DB >> 15716334

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Stéphan Troyanov1, Catherine A Wall, Judith A Miller, James W Scholey, Daniel C Cattran.   

Abstract

Focal and segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases to terminate in ESRD. A complete remission (CR) confers an excellent long-term prognosis, but the quantitative benefits of partial remissions (PR) have not been defined. This study evaluated the rate of renal function decline (slope of creatinine clearance) and renal survival in nephrotic FSGS patients with CR, PR, or no remission. It also examined relapse rate from remission and its impact on outcome. Multivariate analysis included clinical and laboratory data at presentation and over follow-up, BP control, the agents used, and immunosuppressive therapy. The study cohort was 281 nephrotic FSGS patients who had a minimum of 12 mo of observation and were identified from the Toronto Glomerulonephritis Registry. Over a median follow-up of 65 mo, 55 experienced a CR, 117 had a PR, and 109 had no remission. A PR was independently predictive of slope and survival from renal failure by multivariate analysis (adjusted time-dependent hazard ratio, 0.48; 95% confidence interval, 0.24 to 0.96; P = 0.04). Immunosuppression with high-dose prednisone was associated with a higher rate of PR and CR. Relapse from PR was frequent (56%) and associated with a more rapid rate of renal function decline and worse renal survival compared with relapse-free partial remitters. Only female gender and the nadir of proteinuria during remission were associated with a sustained remission. A PR in proteinuria and its maintenance are important therapeutic targets in FSGS, with implications for both slowing progression rate and improving renal survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716334     DOI: 10.1681/ASN.2004070593

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  98 in total

1.  Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Authors:  Monique E Cho; Mary H Branton; David A Smith; Linda Bartlett; Lilian Howard; James C Reynolds; Donald Rosenstein; Sanjeev Sethi; M Berenice Nava; Laura Barisoni; Fernando C Fervenza; Jeffrey B Kopp
Journal:  Am J Nephrol       Date:  2019-04-09       Impact factor: 3.754

2.  Differential risk of remission and ESRD in childhood FSGS.

Authors:  Debbie S Gipson; Hyunsook Chin; Trevor P Presler; Caroline Jennette; Maria E Ferris; Susan Massengill; Keisha Gibson; David B Thomas
Journal:  Pediatr Nephrol       Date:  2006-01-05       Impact factor: 3.714

Review 3.  Glomerular diseases: FSGS.

Authors:  Bhadran Bose; Daniel Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 4.  Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Authors:  Hernán Trimarchi
Journal:  World J Nephrol       Date:  2013-11-06

Review 5.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

6.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

7.  Biological Variability of Estimated GFR and Albuminuria in CKD.

Authors:  Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Shelley Hurwitz; Chi-Yuan Hsu; Harold I Feldman; Dawei Xie; Kathleen D Liu; Theodore E Mifflin; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Joseph V Bonventre; Lesley A Inker; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2018-07-18       Impact factor: 8.860

8.  The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Authors:  Marie C Hogan; Heather N Reich; Peter J Nelson; Sharon G Adler; Daniel C Cattran; Gerald B Appel; Debbie S Gipson; Matthias Kretzler; Jonathan P Troost; John C Lieske
Journal:  Kidney Int       Date:  2016-08-12       Impact factor: 10.612

9.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

10.  Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis.

Authors:  Sean J Barbour; Daniel C Cattran; Gabriela Espino-Hernandez; Michelle A Hladunewich; Heather N Reich
Journal:  Kidney Int       Date:  2015-08-19       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.